Crown Bioscience
About Crown Bioscience
Crown Bioscience is a Healthcare company based in Santa Clara (United States) founded in 2006, and was acquired by Aidikang Medical Laboratory Center in November 2025. Cancer and CVMD drugs are developed using PDX models. Crown Bioscience has raised $85.87 million across 4 funding rounds from investors including Orbimed, JSR Corporation and European Union. The company has 18 employees. Crown Bioscience has completed 3 acquisitions, including OcellO, PRECOS and PreClinOmics. Its chief executive, as recorded, is Armin Spura. Its website crownbio.com draws about 77 thousand monthly visits. Crown Bioscience offers products and services including PDX Models, CDX Models, Syngeneic Models, Organoids, and Bioinformatics Services. Its focus areas include Biopharma Outsourcing, CRO and Drug Discovery. Its legal entity is CROWN BIOSCIENCE, INC. Its competitors include Alloy Therapeutics, NIH and STAQ Pharma; 2 of its 3 listed competitors have raised funding.
Company details
Crown Bioscience develops drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases). The companys proprietary platform includes HuPrime that is a patient-derived xenograft (PDX) models which can be used for efficacy testing. It also offers oncology services, such as oncology databases, ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical models (PDX, Humanized and Murine efficacyPD) for CAR-T Therapy Evaluation (immuno-oncology) etc., CrownBio also has a variety of rodent and mouse models for the development of drugs for CVMD. The company also offers products, such as antibodies for in vivo and in-vitro studies, tissues for CVMD research, tumor samples for Oncology RD, cytokines and growth factors for use in basic and preclinical research, recombinant proteins and cell lines for biological studies, immune checkpoint antibodies and tumor tissue microarrays. CrownBio has strategic partnerships with Xstrahl, a designer, and manufacturer of X-Ray solutions for radiation biology research and Horizon Discovery, a provider of advanced research tools and services for the development of personalized medicines. CrownBio acquired PreClinOmics, an in vivo preclinical company specializing in CVMD and renal disease research. The company has spun-off CBT pharmacueticals, an emerging life science oncology company.
- Headquarters Santa Clara, United States
- Employees 18
- Stage Acquired
- SectorsHealthcare
- Website crownbio.com
- Social LinkedIn X Facebook
- Acquired by JSR Corporation (Dec 2017)
- Legal Name Crown Bioscience, Inc.
Products & Services of Crown Bioscience
Crown Bioscience offers a comprehensive portfolio of products and services, including PDX Models, CDX Models, Syngeneic Models, Organoids, and Bioinformatics Services.
Preclinical models for testing oncology drugs in humanized mice.
Cell-derived xenograft models for cancer research applications.
Models for immuno-oncology studies using immune-competent mice.
3D cell cultures for evaluating drug responses in oncology.
Tools for genomics and proteomics data in drug development.
Funding Insights of Crown Bioscience
Crown Bioscience has successfully raised a total of $85.87M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $159.68 thousand completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85.87M
- Total Rounds 4
- Last Round Grant — $159,679
- First Round $28.8M
(May 2011)
- Investors Count 8
All 4 funding rounds of Crown Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $159,679 | Grant | – | – | |
| May 2014 | $26.6M | Series C | – | – | |
| Jul 2013 | $30.47M | Series C | – | Orbimed, Qiming Venture Partners | – |
| May 2011 | $28.8M | Series C | – | Orbimed, Argonaut Private Equity |
10 investors in total: 10 institutional.
Investors in Crown Bioscience
Crown Bioscience has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, JSR Corporation and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
| cidgroup.com | ||||
Multiple sectors are invested in by Argonaut Private Equity fund. | argonautpe.com | Tulsa, United States | ||
Sector-agnostic investments are made in early-stage Asia Pacific startups. | 1959 | cdibcapitalgroup.com | Taipei, Taiwan | |
Investment services in Chinese SMART sectors are provided by the company. | crcicapital.com | Hong Kong, Hong Kong | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
| lillyasiaventures.com | ||||
Petrochemical products and materials are supplied globally for key industries. | 1957 | jsr.co.jp | Tokyo, Japan | |
Pathology lab services are delivered via a nationwide chain. | 2004 | adicon.com.cn | Hangzhou, China |
Investor details for Crown Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Crown Bioscience
1 people are tracked at Crown Bioscience (1 in leadership); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Armin Spura | CEO | Leadership |
Complete people profiles for Crown Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Crown Bioscience
Crown Bioscience has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include OcellO, PRECOS and PreClinOmics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
3D screening services for drug discovery are offered. | ocello.nl | Leiden, Netherlands | 2011 | May 2021 | •••• | |
Contract research organization (CRO) with expertise in Metabolic, Renal and Cardiovascular disease | preclinomics.com | Indianapolis, United States | 2001 | Mar 2016 | •••• | |
Preclinical oncology services with xenograft and metastatic models are provided. | precos.co.uk | United Kingdom | 2010 | Jul 2013 | •••• |
Complete acquisition details for Crown Bioscience
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Crown Bioscience
9 dated milestones of Crown Bioscience across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Crown Bioscience is founded.
- Funding First funding round of $28.8M.
- Acquisition Acquires PRECOS.
- Acquisition Acquires PreClinOmics.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $160K.
- Exit Acquired by JSR Corporation.
- Acquisition Acquires OcellO.
- Exit Acquired by Aidikang Medical Laboratory Center.
Competitors of Crown Bioscience
Crown Bioscience has 3 listed competitors in our database, 2 of them funded. They include Alloy Therapeutics, NIH and STAQ Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alloytx.com | 2017 | Lexington, United States | $157M | Drug discovery services are provided for therapeutic development. | ||
| nih.gov | 1887 | United States | Drug discovery services are provided to the biopharma sector. | |||
| staqpharma.com | 2018 | Denver, United States | $33.52M | 30 | Drug discovery services are provided for pharmaceutical innovation. |
Detailed competitors of Crown Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Crown Bioscience
The website of Crown Bioscience (crownbio.com) receives about 77K visits a month.
- Monthly visits77K
▲ 32.7% vs previous month
Websites whose visitors overlap most with Crown Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocare.net | 100% | 23.2K | #1,197,634 | View details | |
| taconic.com | 94% | 49.8K | #707,498 | View details | |
| lipomics.com | 90% | View details | |||
medkoo.com | medkoo.com | 89% | #640,352 | – | |
| facellitate.com | 89% | 32K | #997,034 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for Crown Bioscience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Crown Bioscience (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Crown Bioscience
Complete news archive for Crown Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crown Bioscience
Crown Bioscience was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Crown Bioscience is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Armin Spura is the CEO of Crown Bioscience, as recorded in our data.
Crown Bioscience is a funded company, having raised a total of $85.87M across 4 funding rounds to date. The company's 1st funding round was a Series C of $28.8M, raised on May 2011.
Crown Bioscience has 18 employees.
Crown Bioscience develops drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases). The companys proprietary platform includes HuPrime that is a patient-derived xenograft (PDX) models which can be used for efficacy testing. It also offers oncology services, such as oncology databases, ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical models (PDX, Humanized and Murine efficacyPD) for CAR-T Therapy Evaluation (immuno-oncology) etc., CrownBio also has a variety of rodent and mouse models for the development of drugs for CVMD. The company also offers products, such as antibodies for in vivo and in-vitro studies, tissues for CVMD research, tumor samples for Oncology RD, cytokines and growth factors for use in basic and preclinical research, recombinant proteins and cell lines for biological studies, immune checkpoint antibodies and tumor tissue microarrays. CrownBio has strategic partnerships with Xstrahl, a designer, and manufacturer of X-Ray solutions for radiation biology research and Horizon Discovery, a provider of advanced research tools and services for the development of personalized medicines. CrownBio acquired PreClinOmics, an in vivo preclinical company specializing in CVMD and renal disease research. The company has spun-off CBT pharmacueticals, an emerging life science oncology company.
Crown Bioscience's top competitors include NIH, Alloy Therapeutics and STAQ Pharma.
Crown Bioscience offers PDX Models, CDX Models, Syngeneic Models, Organoids, and Bioinformatics Services.
Crown Bioscience has made 3 acquisitions, including OcellO, PRECOS, and PreClinOmics.
Crown Bioscience has 10 investors. Key investors include Orbimed, JSR Corporation, European Union, Qiming Venture Partners, and CDIB Capital Group.
Crown Bioscience operates through Crown Bioscience, Inc..
Yes. Crown Bioscience was acquired by JSR Corporation in December 2017.